CPNP 2004 Annual Meeting

Symposium Brochure

Symposia Brochure Symposia Brochure

Click on the icon to the right to download the 2004 Industry Symposia Brochure or review the content below for a description of all of the symposia to be offered at the 2004 Annual Meeting. (Note: You will need Adobe Acrobat Reader to view this file.)

Thursday, April 22, 2004 (10:30 AM -- 1:00 PM)

image #

Sponsor: AstraZeneca Pharmaceuticals
Title: PTSD and the Challenging Patient.
Program Location: Westin Chicago River North, Chicago, IL

Overview: The session will focus on challenging symptomatology and comorbidities associated with post-traumatic stress disorder (PTSD), including sleep, anxiety, depression, substance abuse, and personality disorders. We will cover evidence-based pharmacotherapy for PTSD symptoms and comorbidities with an interactive discussion of case examples at the end.

Objectives:

  • Review clinical presentation of PTSD and common comorbidities that may complicate recognition and management.
  • Discuss evidence-based approach to managing refractory symptomatology and comorbidities in the PTSD patient.
  • Strategize best clinical approaches to PTSD treatment via review of patient case studies.


Faculty:

  • Sheila R. Botts, PharmD, BCPP University of Kentucky College of Pharmacy & Lexington VA Medical Center Lexington, Kentucky (Program Chair)
  • Michael G. Carvalho, PharmD, BCPP Manchester VA Medical Center Manchester, New Hampshire
  • John J. Spollen, III, MD University of Arkansas for Medical Sciences & Central Arkansas Veterans Healthcare System Little Rock, Arkansas

 

Agenda: 10:30 am -- 12:30 pm Symposium
  • Welcome & Introductions
  • PTSD: Overview
  • Clinical Challenges in PTSD
  • Pharmacotherapy of PTSD: Beyond SSRIs
  • Interactive Case Presentations

12:30 pm -- 1:00 pm Lunch

Accreditation: Creative Educational Concepts, Inc. is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 245-000-04-010-L01 and will award 2.0 contact hours (0.2 CEUs) of credit. Statement of credit will be issued to those participants completing a CE request form and will be mailed within 10 business days.

Registration: To register for this program, please contact CEC at 1-866-360-1717 or register online at www.CEConcepts.net/CPNP.

 

Thursday, April 22, 2004 from 7:00PM-10:00PM (Dinner Symposium)

image #

Sponsor: Pfizer
Title: Enhancing Patient Care: Evidence Based Approaches to the Use of Atypical Antipsychotics
Program Location: The Westin Chicago River North

Speakers Titles:

  • Selecting the Right Medications: New Challenges in the Antipsychotic Drug Selection
    Henry A. Nasrallah, MD
  • Antipsychotics in Special Populations
    Michael Jann, PharmD
  • Emerging areas in Antipsychotic therapy: Discussing the Unmet Needs
    Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP


Learning Objectives:
At the conclusion of the program, participants should be able to:

  • Describe abnormalities in glucose and lipid metabolism associated with newer antipsychotics;
  • Outline clinical considerations for successful switching between antipsychotic agents and describe the advantages and appropriate use of several switching strategies;
  • Recognize the unmet needs of patients with schizophrenia and identify the clinical management strategies and treatment options that are available to improve a patient’s overall health.

Description: The new atypical antipsychotic agents offer many advantages over the older typical agents by improving negative symptom control while also maintaining control of positive symptoms. These advantages are tempered, however, by health concerns including weight gain, increased prevalence of hyperlipidemia, and diabetes.
Recent advances in the development of atypical antipsychotics now offer clinicians new medication options that provide efficacy in relieving the positive and negative psychiatric symptoms of schizophrenia while maintaining a favorable safety and tolerability profile.
This symposium will review and compare the use of atypical antipsychotics agents in various psychotic disorders with the importance on improving the life span of people with Schizophrenia.

Faculty

Program Chairperson:

  • Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP
    Chairman and Professor
    Department of Pharmacotherapy
    College of Pharmacy
    Washington State University


Guest Speakers:

  • Henry A. Nasrallah, MD
    Associate Dean
    Professor of Psychiatry and Neuroscience
    Department of Psychiatry
    University of Cincinatti
  •  
  • Michael Jann, PharmD
    Mercer University


ACPE info: The University of Texas College of Pharmacy is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.2 CEUs (2 contact hours) of continuing pharmaceutical education.

Program Number #: 067-999-04-018-L01

 

Friday, April 23, 2004 (5:30AM -- 8:00AM)

image #
image #

Sponsor: Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Title: Optimizing Clinical Outcomes in the Management of Psychotic Disorders
Location: The Westin Chicago River North, Chicago, Illinois

Program Overview
Effective management of psychotic disorders requires consideration of the full spectrum of effects for each antipsychotic agent. Although efficacy results from clinical trials give a measure of the direct impact on psychotic symptomatology, in the real world adverse effects may influence treatment adherence and antipsychotic outcomes. In particular, the metabolic adverse effects of weight gain, hyperglycemia, and hyperlipidemia increase cardiovascular risk and impose a burden on overall patient health. This symposium will review the mechanistic evolution of antipsychotic pharmacotherapy and examine the basis for variations in efficacy and adverse effect profiles between generations and within agents of the same generation. The evolving role of antipsychotic pharmacotherapy across the spectrum of psychotic disorders will be emphasized.

Learning Objectives
After attending this symposium, participants should be better able to

  • Discuss the evolution of antipsychotic agents’ mechanisms of action and the implications for efficacy, safety, and tolerability
  • Identify the parameters that may influence the effectiveness of an antipsychotic agent under real-world conditions
  • Evaluate the differential adverse effect profiles of antipsychotic agents and the impact of these adverse effects on overall patient health
  • Describe the evolving role of antipsychotic pharmacotherapy in the management of bipolar disorder and psychotic symptomatology


Faculty

  • Effective Management of Psychosis: A Mechanism-Based Review
    Matthew Fuller, PharmD, BCPS, BCPP, FASHP
    Cleveland VAMC
    Brecksville, Ohio
  • Optimizing Overall Patient Health During Antipsychotic Therapy
    Peter F. Buckley, MB, BCh, BAO
    Medical College of Georgia
    Augusta, Georgia
  •  
  • Evolving Role of Antipsychotic Pharmacotherapy
    Roger W. Sommi, PharmD, BCPP
    University of Missouri-Kansas City
    Kansas City, Missouri

Accreditation:
The Health Science Center for Continuing Medical Education is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned the Universal Program Number 247-000-04-001-LO1 and approved for 1.5 contact hours (0.15 CEUs).

Saturday, April 24, 12-2 p.m.

image #

Sponsor: Eli Lilly & Company
Title: Recognition and Treatment of Bipolar Disorder across the Continuum of Care
Location: The Westin Chicago River North

Program Description:
Although bipolar disorder affects only 1-2% of the population, it challenges clinicians because of its cyclic and progressive nature. Over time, bipolar disorder is associated with significant morbidity and mortality. Therefore it requires that clinicians have a thorough understanding of the efficacy and safety of agents used in both short- and long-term treatment strategies. This symposium will focus on data supporting the use of standard and emerging therapies, including antipsychotics, mood stabilizers, anticonvulsants, and combination therapy. The program will conclude with an in-depth discussion of special concerns in the treatment of patients with bipolar disorder, including adherence and concomitant substance abuse.

Learning Objectives:
At the conclusion of this program, attendees should be able to:

  • Describe the epidemiology, pathophysiology, symptoms, and impact of bipolar disorder.
  • Explain the role and efficacy of the various therapeutic entities used in the treatment of bipolar disorder including antipsychotics, mood stabilizers, anticonvulsants, and combination therapies.
  • Compare and contrast the side effect profiles of drugs used in the treatment of bipolar disorder with an emphasis on how these effects might impact safety and adherence in both short- and long-term therapy.
  • Describe concerns and approaches in treating special patient populations, including those with concomitant substance abuse.

Program Faculty:

  • Robert Dufresne, Ph.D., Ph.D., BCPS, BCPP (Moderator)
    Professor of Pharmacy
    University of Rhode Island
    College of Pharmacy
    and
    Psychiatric Pharmacotherapy Specialist
    Providence Veterans Administration Medical Center
    Providence, Rhode Island
  •  
  • Charles F. Caley, Pharm.D., BCPP
    Associate Clinical Professor
    University of Connecticut
    School of Pharmacy
    Storrs, Connecticut
    and
    Burlingame Research Center
    Institute of Living
    Hartford, Connecticut
  •  
  • Sally Guthrie, Pharm.D., BCPP, FCCP
    Associate Professor
    University of Michigan
    College of Pharmacy
    Ann Arbor, Michigan

ACPE: The American Society of Health-System Pharmacists is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmacy education. The program provides 2.0 hours (0.2 CEUs) of continuing education credit.

Program Number: 204-000-04-401-L01

 

Saturday, April 24, 2004 6:30--10:00 PM Dinner Symposium

image #

Sponsor: Ortho-McNeil Pharmaceutical, Inc.
Title: Advances in the Neurobiology and Treatment of Alcohol and Drug
Dependence
Program Location: Astor Ballroom, The Westin Chicago River North

Overview: Alcoholism and drug dependence are associated with significant and lasting changes in brain chemistry and function. Thus, long-term abstinence following acute detoxification and withdrawal is often difficult to achieve. Recent advances in the understanding of the neurobiology of addictive disorders have laid the groundwork for new approaches to pharmacologic treatment. In particular, many antiepileptic drugs interact with neurotransmitter systems that mediate addiction, and efficacy of selected agents in controlling craving and reducing relapse has been reported. Speakers at this dinner symposium will review current knowledge of the neurobiology of alcohol and drug addiction, molecular targets in the development of new treatments, and promising investigational therapies.

Objectives:
Upon conclusion of this program, attendees should be able to:

  • Describe recent advances in the understanding of the neurobiology of addiction and withdrawal.
  • Explain why detoxification alone is rarely sufficient to help individuals with addictive disorders achieve long-term abstinence.
  • Discuss new developments in the pharmacotherapy of alcohol and cocaine withdrawal and relapse prevention.


Faculty:

  • Developments in the Neurobiology and Treatment of Alcohol Withdrawal
    Hugh L. Myrick, MD
    Assistant Professor
    Center for Drug and Alcohol Programs
    Charleston Alcohol Research Center
    Medical University of South Carolina
    Institute of Psychiatry
  • Current and Experimental Pharmacotherapies for Alcohol Dependence
    Susan Sonne, PharmD, BCPP (Moderator)
    Assistant Professor of Psychiatry
    Clinical Assistant Professor of Pharmacy
    Medical University of South Carolina
    Institute of Psychiatry
  • Advances in the Pharmacotherapy of Cocaine Dependence
    Kyle M. Kampman, MD
    Associate Professor
    Department of Psychiatry
    University of Pennsylvania School of Medicine
    Medical Director
    University of Pennsylvania Treatment Research Center

Accreditation: Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. This program is approved for 2.5 contact hours (0.25 CEUs) of continuing pharmaceutical education credit.

ACPE #: 038-999-04-003-L01